Molecular mechanism of antagonism between the Y181C and E138K mutations in HIV-1 reverse transcriptase

Journal of Virology

Volumn 86, Issue 23, 2012, Pages 12983-12990

  Xu, Hong Tao ^a   Oliveira, Maureen ^a   Asahchop, Eugene L ^a   McCallum, Matthew ^a,b   Quashie, Peter K ^a,b   Han, Yingshan ^a   Quan, Yudong ^a   Wainberg, Mark A ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ETRAVIRINE; NATURAL DEOXYNUCLEOSIDE TRIPHOSPHATE; NUCLEOSIDE; PROTEIN P51; PROTEIN P66; RECOMBINANT ENZYME; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME PURIFICATION; GENETIC VARIABILITY; IC 50; IN VITRO STUDY; MOLECULAR INTERACTION; MONONUCLEAR CELL; MUTATIONAL ANALYSIS; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; STEADY STATE; TISSUE CULTURE; UMBILICAL CORD BLOOD; VIRUS REPLICATION; WILD TYPE;

ANTI-HIV AGENTS; CHROMATOGRAPHY, AFFINITY; DRUG RESISTANCE, VIRAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ESCHERICHIA COLI; HIV REVERSE TRANSCRIPTASE; HIV-1; KINETICS; MUTATION, MISSENSE; PYRIDAZINES; RECOMBINANT PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84869234318     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02005-12     Document Type: Article

References (50)

1. Alcaro S, et al. 2011. Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine. ChemMedChem 6:2203-2213.
2. Ambrose Z, et al. 2009. The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs. J. Virol. 83:3826-3833.
3. Archer RH, et al. 2000. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture. J. Virol. 74:8390-8401.
4. Arts EJ, et al. 1994. Comparison of deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template-switching reaction. J. Biol. Chem. 269:14672-14680.
5. Asahchop EL, et al. 2011. Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes. Antimicrob. Agents Chemother. 55:600-607.
6. Azijn H, et al. 2010. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTIresistant HIV-1. Antimicrob. Agents Chemother. 54:718-727.
7. Back NK, et al. 1996. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 15:4040-4049.
8. Benhamida J, Chappey C, Coakley E, Parkin NT. 2008. HIV-I genotype algorithms for prediction of etravirine susceptibility: novel mutations and weighting factors identified through correlations to phenotype. Antivir. Ther. 13:A142.
9. Caliendo AM, et al. 1996. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication. J. Virol. 70:2146-2153.
10. Croxtall JD. 2012. Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection. Drugs 72:847-869.
11. Debyser Z, et al. 1993. Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus type 1-specific reverse transcriptase inhibitors. Mol. Pharmacol. 43: 521-526.
12. Delaugerre C, et al. 2001. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitorcontaining regimen. J. Med. Virol. 65:445-448.
13. Esnouf R, et al. 1995. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat. Struct. Biol. 2:303-308.
14. Esnouf RM, et al. 1997. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proc. Natl. Acad. Sci. U. S. A. 94:3984-3989.
15. Fuentes GM, Palaniappan C, Fay PJ, Bambara RA. 1996. Strand displacement synthesis in the central polypurine tract region of HIV-1 promotes DNA to DNA strand transfer recombination. J. Biol. Chem. 271: 29605-29611.
16. Gao L, et al. 2008. Apparent defects in processive DNA synthesis, strand transfer, and primer elongation of Met-184 mutants of HIV-1 reverse transcriptase derive solely from a dNTP utilization defect. J. Biol. Chem. 283:9196-9205.
17. Goff SP. 1990. Retroviral reverse transcriptase: synthesis, structure, and function. J. Acquir. Immune Defic. Syndr. 3:817-831.
18. Hirsch MS, et al. 2000. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA panel. JAMA 283:2417-2426.
19. Hsiou Y, et al. 1996. Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure 4:853-860.
20. Hu Z, Kuritzkes DR. 2011. Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1. J. Virol. 85:11309-11314.
21. Janssen PA, et al. 2005. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J. Med. Chem. 48:1901-1909.
22. Kulkarni R, et al. 2012. The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness. J. Acquir. Immune Defic. Syndr. 59:47-54.
23. Larder BA. 1992. 3=-Azido-3=-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 36:2664-2669.
24. Le Grice SF, Cameron CE, Benkovic SJ. 1995. Purification and characterization of human immunodeficiency virus type 1 reverse transcriptase. Methods Enzymol. 262:130-144.
25. Le Grice SF, Gruninger-Leitch F. 1990. Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography. Eur. J. Biochem. 187:307-314.
26. Marcelin AG, et al. 2012. Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen. Antivir. Ther. 17:119-123.
27. Marcelin AG, et al. 2010. Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients. Antimicrob. Agents Chemother. 54:72-77.
28. Naeger LK, Margot NA, Miller MD. 2001. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chainterminator removal and viral replication. Antivir. Ther. 6:115-126.
29. Nissley DV, et al. 2007. Characterization of novel non-nucleoside reverse transcriptase (RT) inhibitor resistance mutations at residues 132 and 135 in the 51 kDa subunit of HIV-1 RT. Biochem. J. 404:151-157.
30. Oliveira M, Brenner BG, Wainberg MA. 2009. Isolation of drug-resistant mutant HIV variants using tissue culture drug selection. Methods Mol. Biol. 485:427-433.
31. Pandey PK, et al. 2002. Insertion of a small peptide of six amino acids into the β7-β8 loop of the p51 subunit of HIV-1 reverse transcriptase perturbs the heterodimer and affects its activities. BMC Biochem. 3:18.
32. Pandey PK, Kaushik N, Talele TT, Yadav PN, Pandey VN. 2001. The β7-β8 loop of the p51 subunit in the heterodimeric (p66/p51) human immunodeficiency virus type 1 reverse transcriptase is essential for the catalytic function of the p66 subunit. Biochemistry 40:9505-9512.
33. Quan Y, et al. 2003. Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C. AIDS Res. Hum. Retroviruses 19:743-753.
34. Ren J, et al. 1998. Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives. Biochemistry 37:14394-14403.
35. Schader SM, et al. 2012. In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine. Antimicrob. Agents Chemother. 56:751-756.
36. Selmi B, et al. 2003. The Y181C substitution in 3=-azido-3=-deoxythymidine-resistant human immunodeficiency virus, type 1, reverse transcriptase suppresses the ATP-mediated repair of the 3=-azido-3=-deoxythymidine 5=-monophosphate-terminated primer. J. Biol. Chem. 278:40464-40472.
37. Sharma PL, Crumpacker CS. 1999. Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val. J. Virol. 73:8448-8456.
38. Sluis-Cremer N, Temiz NA, Bahar I. 2004. Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Curr. HIV Res. 2:323-332.
39. Smerdon SJ, et al. 1994. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U. S. A. 91:3911-3915.
40. Spence RA, Anderson KS, Johnson KA. 1996. HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors. Biochemistry 35:1054-1063.
41. Tambuyzer L, Nijs S, Daems B, Picchio G, Vingerhoets J. 2011. Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine. J. Acquir. Immune Defic. Syndr. 58:18-22.
42. Tambuyzer L, et al. 2010. Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirinecontaining regimen in the DUET-1 and DUET-2 clinical studies. AIDS Res. Hum. Retroviruses 26:1197-1205.
43. Vingerhoets J, et al. 2005. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J. Virol. 79:12773-12782.
44. Vingerhoets J, et al. 2010. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled phase III clinical studies. AIDS 24:503-514.
45. Wainberg MA. 2003. HIV resistance to nevirapine and other nonnucleoside reverse transcriptase inhibitors. J. Acquir. Immune Defic. Syndr. 34(Suppl 1):S2-S7.
46. Xu H, et al. 2009. Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine. Antimicrob. Agents Chemother. 53:4667-4672.
47. Xu HT, et al. 2011. Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J. Virol. 85:11300-11308.
48. Xu HT, Oliveira M, Quan Y, Bar-Magen T, Wainberg MA. 2010. Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function. J. Antimicrob. Chemother. 65:2291-2299.
49. Xu HT, et al. 2012. Subunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase. J. Virol. 86:8422-8431.
50. Xu HT, et al. 2010. Comparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype C. Retrovirology 7:80.